Loading...

FITC anti-human CD90 (Thy1) Antibody FITC anti-human CD90 (Thy1) Antibody

Pricing & Availability
Clone
5E10 (See other available formats)
Regulatory Status
RUO
Workshop
HCDM listed
Other Names
Thy-1, Thy1
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
5E10_FITC_020708
Human erythroleukemic cell line (HEL) stained with 5E10 FITC
  • 5E10_FITC_020708
    Human erythroleukemic cell line (HEL) stained with 5E10 FITC
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
328107 25 tests DKK600
Check Availability


Need larger quantities of this item?
Request Bulk Quote
328108 100 tests DKK1361
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD90 is a 25-35 kD GPI-anchored protein, also known as Thy-1. It belongs to the Ig superfamily. Human CD90 is expressed on neuronal cells, a subset of CD34+ cells, a subset of fetal liver cells and fetal thymocytes, fibroblasts, activated endothelial cells, and some leukemia cell lines. CD34+CD90+ cells are primitive hematopoietic stem cells. It has been reported that Thy-1 binds with β2 and β3 integrins and plays bimodal roles in the regulation of cell adhesion and neurite outgrowth, and inhibits hematopoietic stem cells proliferation and differentiation.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Reported Reactivity
African Green, Baboon, Cynomolgus, Pigtailed Macaque, Rhesus, Pig
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
HEL cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Clone 5E10 recognizes an epitope on Thy-1 independent of its glycosylation, but is abolished under reducing conditions.4 Additional reported (for the relevant formats) applications include: immunohistochemical staining of acetone-fixed frozen sections, immunoprecipitation1, and immunofluorescence3.

Application References
  1. Craig W, et al. 1993. J. Exp. Med. 177:1331. (IP)
  2. Gundlach CW 4th, et al. 2011. Bioconjug. Chem. 22:1706. (Pig Reactivity)
  3. Touboul C, et al. 2013. J. Transl. Med. 11:28. (IF)
  4. Bradley JE, et al. 2013. Lab Invest. 93:365. (Epitope)
  5. Donnenberg VS, et al. 2010. Cytometry B. Clin. Cytom. 5:287. (IHC)
Product Citations
  1. Camerlingo R, et al. 2011. Lung Cancer. 72:23. PubMed
  2. Liu T, et al. 2020. Biochem Biophys Res Commun. 532:385. PubMed
  3. Zhang T, et al. 2022. IUBMB Life. 74:1081. PubMed
  4. Yüce M, et al. 2022. J Cell Biochem. 123:1966. PubMed
  5. Albayrak E, et al. 2022. J Cell Biochem. 123:2009. PubMed
  6. Wang H, et al. 2022. Oxid Med Cell Longev. 2022:3082969. PubMed
  7. Ferreira-Baptista C, et al. 2022. Bioengineering (Basel). 9: . PubMed
  8. Fu H, et al. 2023. Regen Ther. 22:7. PubMed
  9. Lin L, et al. 2023. Mol Ther Nucleic Acids. 31:88. PubMed
  10. Chen X, et al. 2023. Exp Ther Med. 25:99. PubMed
  11. Lee CW, et al. 2022. J Adv Res. 39:73. PubMed
  12. Bowley TY, et al. 2022. Cancer Res Commun. 2:1436. PubMed
  13. Hua J, et al. 2023. Ann Transl Med. 11:62. PubMed
  14. Uzieliene I, et al. 2023. Int J Mol Sci. 24:. PubMed
  15. Pal D, et al. 2023. Nat Commun. 14:1129. PubMed
  16. Che L, et al. 2023. Foods. 12:. PubMed
  17. Wan L, et al. 2023. PeerJ. 11:e15164. PubMed
  18. Ishiuchi N, et al. 2023. Stem Cell Res Ther. 14:121. PubMed
  19. Lu Y, et al. 2023. Sci Rep. 13:8479. PubMed
  20. Hu H, et al. 2023. Front Mol Neurosci. 16:1179175. PubMed
  21. Miksiunas R, et al. 2021. Int J Mol Sci. 22:. PubMed
  22. Wu J, et al. 2022. Nat Commun. 13:676. PubMed
  23. Peng K, et al. 2020. Sci Rep. 10:18433. PubMed
  24. Yan H, et al. 2020. Adv Sci (Weinh). 7:1903516. PubMed
  25. Xin Y, et al. 2021. Stem Cell Res Ther. 49:12. PubMed
  26. Li L, et al. 2015. Int J Pharmaceutics. 488: 1-11. PubMed
  27. Liu X, et al. 2020. Exp Ther Med. 1.258333333. PubMed
  28. Chen X, et al. 2022. Front Bioeng Biotechnol. 10:915181. PubMed
  29. Yu XX, et al. 2021. Cell Res. 31:886. PubMed
  30. Radhakrishnan S, et al. 2019. Mol Med Rep. 20:813. PubMed
  31. Shi L, et al. 2021. Stem Cell Res Ther. 12:147. PubMed
  32. Huang X, et al. 2019. Oxid Med Cell Longev. 2019:1305049. PubMed
  33. Vishnoi M, et al. 2018. Cancer Res. 78:5349. PubMed
  34. Tu S, et al. 2020. Cellular Signalling. 73:109695. PubMed
  35. Guney-Esken G, et al. 2021. Stem Cell Res Ther. 12:287. PubMed
  36. Takao T, et al. 2022. STAR Protoc. 3:101786. PubMed
  37. Qin XY, et al. 2020. Cell Death Dis. 0.504166667. PubMed
  38. Hwang Y, et al. 2021. Int J Mol Sci. 22:. PubMed
  39. Dregalla RC, et al. 2021. Stem Cell Res Ther. 12:547. PubMed
  40. Nguyen MAT, et al. 2020. Immunohorizons. 0.465277778. PubMed
  41. Han X, et al. 2020. Int J Oral Sci. 12:10. PubMed
  42. Liu Z, et al. 2021. Molecules. 26:. PubMed
  43. Sun W, et al. 2019. Exp Ther Med. 17:2199. PubMed
  44. Hanse E, et al. 2017. Oncogene. 10.1038/onc.2017.36. PubMed
  45. Albayrak E, et al. 2021. J Cell Physiol. 236:8122. PubMed
  46. Liu Y, et al. 2022. iScience. 25:104405. PubMed
  47. Yu C, et al. 2020. Sci Rep. 10:14521. PubMed
  48. Yan K, et al. 2022. iScience. 25:104822. PubMed
  49. Kinchen J et al. 2018. Cell. 175(2):372-386 . PubMed
  50. Gao P, et al. 2017. Cytotechnology. 69:751. PubMed
  51. Nguyen JT, et al. 2019. iScience. 17:190. PubMed
  52. DAgostino S, et al. 2021. Frontiers in Oncology. 10:600980. PubMed
  53. Duan X, et al. 2022. Cell Biosci. 12:60. PubMed
  54. Fawkner-Corbett D, et al. 2021. STAR Protoc. 2:100890. PubMed
  55. Yang C et al. 2019. Int J Mol Med. 43(3):1395-1405 . PubMed
  56. Zhang S, et al. 2021. Stem Cells Int. 6616240:2021. PubMed
  57. Uslu M, et al. 2020. J Cell Physiol. 235:9644. PubMed
  58. Tidu F, et al. 2021. iScience. 24(6):102683. PubMed
  59. Ayhan S, et al. 2021. Journal of Cell Science. 134(6):. PubMed
  60. Zhang Y, et al. 2019. Aging (Albany NY). 11:12641. PubMed
  61. Cai S, et al. 2022. Cell Biosci. 12:115. PubMed
  62. Zhang Y, et al. 2018. Stem Cells Int. 2018:7159465. PubMed
  63. Noz MP, et al. 2020. Elife. 9:00. PubMed
  64. Sun T, et al. 2019. Haematologica. 105:661. PubMed
  65. Guney-Esken G, et al. 2021. Methods Mol Biol. 2549:23. PubMed
  66. Motedayyen H, et al. 2017. BMC Res Notes. . 10.1186/s13104-017-2880-6. PubMed
  67. Narakornsak S, et al. 2017. Acta Histochemica. 10.1016/j.acthis.2017.04.006. PubMed
  68. Keshtkar S, et al. 2021. Stem Cells Int. 8857457:2020. PubMed
  69. Okamura G, et al. 2020. Int J Mol Sci. 22:00. PubMed
  70. Zhang H, et al. 2017. Oncogene. 10.1038/onc.2016.512. PubMed
  71. Aomatsu E, et al. 2014. Sci Rep. 4:3652. PubMed
  72. Miksiunas R, et al. 2022. Cells. 11:. PubMed
  73. He Z, et al. 2020. J Exp Clin Cancer Res. 39:140. PubMed
  74. Xu L, et al. 2022. Int J Mol Sci. 23:. PubMed
  75. Fawkner-Corbett D, et al. 2021. Cell. 184(3):810-826.e23. PubMed
  76. Meng Z, et al. 2013. Mol Cancer Ther. 12:2067. PubMed
  77. He H, et al. 2019. J Cell Mol Med. 23:4139. PubMed
  78. Zhu YP et al. 2018. Cell reports. 24(9):2329-2341 . PubMed
  79. Pauken CM, et al. 2021. Cancers (Basel). 13:. PubMed
  80. Patel C, et al. 2022. Curr Protoc. 2:e400. PubMed
  81. Vishnoi M, et al. 2019. Mol Oncol. 13(9): 1913. PubMed
  82. Putra I, et al. 2021. Transl Vis Sci Technol. 10:3. PubMed
  83. Matheni C, et al. 2021. Cell J. 23:145. PubMed
  84. Miksiunas R, et al. 2020. Int J Mol Sci. 21:00. PubMed
  85. Luzuriaga J, et al. 2020. Biomedicines. 8:00. PubMed
  86. Hong Y, et al. 2020. Aging Cell. 19:e13128. PubMed
  87. Dinh HQ, et al. 2020. Immunity. 53(2):319-334.e6. PubMed
  88. Thiel A, et al. 2015. Sci Rep. 5: 17685. PubMed
  89. Chijimatsu R, et al. 2022. Regen Ther. 21:52. PubMed
  90. Shang W, et al. 2022. Dis Markers. 2022:7286645. PubMed
  91. Sprouse ML, et al. 2019. Int J Mol Sci. 20:8. PubMed
  92. Khanh VC, et al. 2021. Stem Cells Dev. 30:758. PubMed
  93. Camerlingo R, et al. 2011. Lung Cancer. 72:23. PubMed
  94. Liu T, et al. 2020. Biochem Biophys Res Commun. 532:385. PubMed
  95. Zhang T, et al. 2022. IUBMB Life. 74:1081. PubMed
  96. Yüce M, et al. 2022. J Cell Biochem. 123:1966. PubMed
  97. Albayrak E, et al. 2022. J Cell Biochem. 123:2009. PubMed
  98. Wang H, et al. 2022. Oxid Med Cell Longev. 2022:3082969. PubMed
  99. Ferreira-Baptista C, et al. 2022. Bioengineering (Basel). 9: . PubMed
  100. Fu H, et al. 2023. Regen Ther. 22:7. PubMed
  101. Lin L, et al. 2023. Mol Ther Nucleic Acids. 31:88. PubMed
  102. Chen X, et al. 2023. Exp Ther Med. 25:99. PubMed
  103. Lee CW, et al. 2022. J Adv Res. 39:73. PubMed
  104. Bowley TY, et al. 2022. Cancer Res Commun. 2:1436. PubMed
  105. Hua J, et al. 2023. Ann Transl Med. 11:62. PubMed
  106. Uzieliene I, et al. 2023. Int J Mol Sci. 24:. PubMed
  107. Pal D, et al. 2023. Nat Commun. 14:1129. PubMed
  108. Che L, et al. 2023. Foods. 12:. PubMed
  109. Wan L, et al. 2023. PeerJ. 11:e15164. PubMed
  110. Ishiuchi N, et al. 2023. Stem Cell Res Ther. 14:121. PubMed
  111. Lu Y, et al. 2023. Sci Rep. 13:8479. PubMed
  112. Hu H, et al. 2023. Front Mol Neurosci. 16:1179175. PubMed
  113. Miksiunas R, et al. 2021. Int J Mol Sci. 22:. PubMed
  114. Wu J, et al. 2022. Nat Commun. 13:676. PubMed
  115. Peng K, et al. 2020. Sci Rep. 10:18433. PubMed
  116. Yan H, et al. 2020. Adv Sci (Weinh). 7:1903516. PubMed
  117. Xin Y, et al. 2021. Stem Cell Res Ther. 49:12. PubMed
  118. Li L, et al. 2015. Int J Pharmaceutics. 488: 1-11. PubMed
  119. Liu X, et al. 2020. Exp Ther Med. 1.258333333. PubMed
  120. Chen X, et al. 2022. Front Bioeng Biotechnol. 10:915181. PubMed
  121. Yu XX, et al. 2021. Cell Res. 31:886. PubMed
  122. Radhakrishnan S, et al. 2019. Mol Med Rep. 20:813. PubMed
  123. Shi L, et al. 2021. Stem Cell Res Ther. 12:147. PubMed
  124. Huang X, et al. 2019. Oxid Med Cell Longev. 2019:1305049. PubMed
  125. Vishnoi M, et al. 2018. Cancer Res. 78:5349. PubMed
  126. Tu S, et al. 2020. Cellular Signalling. 73:109695. PubMed
  127. Guney-Esken G, et al. 2021. Stem Cell Res Ther. 12:287. PubMed
  128. Takao T, et al. 2022. STAR Protoc. 3:101786. PubMed
  129. Qin XY, et al. 2020. Cell Death Dis. 0.504166667. PubMed
  130. Hwang Y, et al. 2021. Int J Mol Sci. 22:. PubMed
  131. Dregalla RC, et al. 2021. Stem Cell Res Ther. 12:547. PubMed
  132. Nguyen MAT, et al. 2020. Immunohorizons. 0.465277778. PubMed
  133. Han X, et al. 2020. Int J Oral Sci. 12:10. PubMed
  134. Liu Z, et al. 2021. Molecules. 26:. PubMed
  135. Sun W, et al. 2019. Exp Ther Med. 17:2199. PubMed
  136. Hanse E, et al. 2017. Oncogene. 10.1038/onc.2017.36. PubMed
  137. Albayrak E, et al. 2021. J Cell Physiol. 236:8122. PubMed
  138. Liu Y, et al. 2022. iScience. 25:104405. PubMed
  139. Yu C, et al. 2020. Sci Rep. 10:14521. PubMed
  140. Yan K, et al. 2022. iScience. 25:104822. PubMed
  141. Kinchen J et al. 2018. Cell. 175(2):372-386 . PubMed
  142. Gao P, et al. 2017. Cytotechnology. 69:751. PubMed
  143. Nguyen JT, et al. 2019. iScience. 17:190. PubMed
  144. DAgostino S, et al. 2021. Frontiers in Oncology. 10:600980. PubMed
  145. Duan X, et al. 2022. Cell Biosci. 12:60. PubMed
  146. Fawkner-Corbett D, et al. 2021. STAR Protoc. 2:100890. PubMed
  147. Yang C et al. 2019. Int J Mol Med. 43(3):1395-1405 . PubMed
  148. Zhang S, et al. 2021. Stem Cells Int. 6616240:2021. PubMed
  149. Uslu M, et al. 2020. J Cell Physiol. 235:9644. PubMed
  150. Tidu F, et al. 2021. iScience. 24(6):102683. PubMed
  151. Ayhan S, et al. 2021. Journal of Cell Science. 134(6):. PubMed
  152. Zhang Y, et al. 2019. Aging (Albany NY). 11:12641. PubMed
  153. Cai S, et al. 2022. Cell Biosci. 12:115. PubMed
  154. Zhang Y, et al. 2018. Stem Cells Int. 2018:7159465. PubMed
  155. Noz MP, et al. 2020. Elife. 9:00. PubMed
  156. Sun T, et al. 2019. Haematologica. 105:661. PubMed
  157. Guney-Esken G, et al. 2021. Methods Mol Biol. 2549:23. PubMed
  158. Motedayyen H, et al. 2017. BMC Res Notes. . 10.1186/s13104-017-2880-6. PubMed
  159. Narakornsak S, et al. 2017. Acta Histochemica. 10.1016/j.acthis.2017.04.006. PubMed
  160. Keshtkar S, et al. 2021. Stem Cells Int. 8857457:2020. PubMed
  161. Okamura G, et al. 2020. Int J Mol Sci. 22:00. PubMed
  162. Zhang H, et al. 2017. Oncogene. 10.1038/onc.2016.512. PubMed
  163. Aomatsu E, et al. 2014. Sci Rep. 4:3652. PubMed
  164. Miksiunas R, et al. 2022. Cells. 11:. PubMed
  165. He Z, et al. 2020. J Exp Clin Cancer Res. 39:140. PubMed
  166. Xu L, et al. 2022. Int J Mol Sci. 23:. PubMed
  167. Fawkner-Corbett D, et al. 2021. Cell. 184(3):810-826.e23. PubMed
  168. Meng Z, et al. 2013. Mol Cancer Ther. 12:2067. PubMed
  169. He H, et al. 2019. J Cell Mol Med. 23:4139. PubMed
  170. Zhu YP et al. 2018. Cell reports. 24(9):2329-2341 . PubMed
  171. Pauken CM, et al. 2021. Cancers (Basel). 13:. PubMed
  172. Patel C, et al. 2022. Curr Protoc. 2:e400. PubMed
  173. Vishnoi M, et al. 2019. Mol Oncol. 13(9): 1913. PubMed
  174. Putra I, et al. 2021. Transl Vis Sci Technol. 10:3. PubMed
  175. Matheni C, et al. 2021. Cell J. 23:145. PubMed
  176. Miksiunas R, et al. 2020. Int J Mol Sci. 21:00. PubMed
  177. Luzuriaga J, et al. 2020. Biomedicines. 8:00. PubMed
  178. Hong Y, et al. 2020. Aging Cell. 19:e13128. PubMed
  179. Dinh HQ, et al. 2020. Immunity. 53(2):319-334.e6. PubMed
  180. Thiel A, et al. 2015. Sci Rep. 5: 17685. PubMed
  181. Chijimatsu R, et al. 2022. Regen Ther. 21:52. PubMed
  182. Shang W, et al. 2022. Dis Markers. 2022:7286645. PubMed
  183. Sprouse ML, et al. 2019. Int J Mol Sci. 20:8. PubMed
  184. Khanh VC, et al. 2021. Stem Cells Dev. 30:758. PubMed
RRID
AB_893438 (BioLegend Cat. No. 328107)
AB_893429 (BioLegend Cat. No. 328108)

Antigen Details

Structure
25-35 kD glycoprotein, Ig superfamily
Distribution

Subset of CD34+ hematopoietic stem cells, subset of fetal thymocytes, subset of fetal liver cells, fibroblast, activated endothelial cells, neurons and some leukemia cell lines

Function
Regulate hematopoiesis and neural cell growth, cell adhesion
Ligand/Receptor
β3 integrin, β2 integrin
Cell Type
Endothelial cells, Fibroblasts, Hematopoietic stem and progenitors, Leukemia, Mesenchymal Stem Cells, Neurons, Thymocytes
Biology Area
Immunology, Stem Cells
Molecular Family
CD Molecules
Antigen References

1. McKenzie JL, et al. 1981. J. Immunol. 126:843.
2. Avalos AM, et al. 2002. Biol. Res. 35:231.
3. Wetzel A, et al. 2004. J. Immunol. 172:3850.

Gene ID
7070 View all products for this Gene ID
UniProt
View information about CD90 on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD90 Reagents Request Custom Conjugation
Description Clone Applications
PE/Cyanine7 anti-human CD90 (Thy1) 5E10 FC
Purified anti-human CD90 (Thy1) 5E10 FC,CyTOF®,IHC-F,ICC,IP
Biotin anti-human CD90 (Thy1) 5E10 FC
FITC anti-human CD90 (Thy1) 5E10 FC
PE anti-human CD90 (Thy1) 5E10 FC
PE/Cyanine5 anti-human CD90 (Thy1) 5E10 FC
APC anti-human CD90 (Thy1) 5E10 FC
Alexa Fluor® 647 anti-human CD90 (Thy1) 5E10 FC
PerCP/Cyanine5.5 anti-human CD90 (Thy1) 5E10 FC
Alexa Fluor® 700 anti-human CD90 (Thy1) 5E10 FC
Brilliant Violet 421™ anti-human CD90 (Thy1) 5E10 FC
Brilliant Violet 510™ anti-human CD90 (Thy1) 5E10 FC
Brilliant Violet 605™ anti-human CD90 (Thy1) 5E10 FC
Purified anti-human CD90 (Thy1) (Maxpar® Ready) 5E10 FC,CyTOF®
APC/Cyanine7 anti-human CD90 (Thy1) 5E10 FC
PE/Dazzle™ 594 anti-human CD90 (Thy1) 5E10 FC
APC/Fire™ 750 anti-human CD90 (Thy1) 5E10 FC
Brilliant Violet 711™ anti-human CD90 (Thy1) 5E10 FC
TotalSeq™-A0060 anti-human CD90 (Thy1) 5E10 PG
Brilliant Violet 785™ anti-human CD90 (Thy1) 5E10 FC
Brilliant Violet 650™ anti-human CD90 (Thy1) 5E10 FC
TotalSeq™-C0060 anti-human CD90 (Thy1) 5E10 PG
TotalSeq™-B0060 anti-human CD90 (Thy1) 5E10 PG
TotalSeq™-D0060 anti-human CD90 (Thy1) 5E10 PG
Spark Red™ 718 anti-human CD90 (Thy1) (Flexi-Fluor™) 5E10 FC
Spark Blue™ 574 anti-human CD90 (Thy1) (Flexi-Fluor™) 5E10 FC
Spark Blue™ 550 anti-human CD90 (Thy1) (Flexi-Fluor™) 5E10 FC
Spark PLUS UV395™ anti-human CD90 (Thy1) 5E10 FC
Go To Top Version: 3    Revision Date: 08/04/2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
5E10 (See other available formats)
Regulatory Status
RUO
Workshop
HCDM listed
Other Names
Thy-1, Thy1
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
5E10_FITC_020708
Human erythroleukemic cell line (HEL) stained with 5E10 FITC
  • 5E10_FITC_020708
    Human erythroleukemic cell line (HEL) stained with 5E10 FITC
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
328107 25 tests DKK600
Check Availability


Need larger quantities of this item?
Request Bulk Quote
328108 100 tests DKK1361
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD90 is a 25-35 kD GPI-anchored protein, also known as Thy-1. It belongs to the Ig superfamily. Human CD90 is expressed on neuronal cells, a subset of CD34+ cells, a subset of fetal liver cells and fetal thymocytes, fibroblasts, activated endothelial cells, and some leukemia cell lines. CD34+CD90+ cells are primitive hematopoietic stem cells. It has been reported that Thy-1 binds with β2 and β3 integrins and plays bimodal roles in the regulation of cell adhesion and neurite outgrowth, and inhibits hematopoietic stem cells proliferation and differentiation.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Reported Reactivity
African Green, Baboon, Cynomolgus, Pigtailed Macaque, Rhesus, Pig
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
HEL cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Clone 5E10 recognizes an epitope on Thy-1 independent of its glycosylation, but is abolished under reducing conditions.4 Additional reported (for the relevant formats) applications include: immunohistochemical staining of acetone-fixed frozen sections, immunoprecipitation1, and immunofluorescence3.

Application References
  1. Craig W, et al. 1993. J. Exp. Med. 177:1331. (IP)
  2. Gundlach CW 4th, et al. 2011. Bioconjug. Chem. 22:1706. (Pig Reactivity)
  3. Touboul C, et al. 2013. J. Transl. Med. 11:28. (IF)
  4. Bradley JE, et al. 2013. Lab Invest. 93:365. (Epitope)
  5. Donnenberg VS, et al. 2010. Cytometry B. Clin. Cytom. 5:287. (IHC)
Product Citations
  1. Camerlingo R, et al. 2011. Lung Cancer. 72:23. PubMed
  2. Liu T, et al. 2020. Biochem Biophys Res Commun. 532:385. PubMed
  3. Zhang T, et al. 2022. IUBMB Life. 74:1081. PubMed
  4. Yüce M, et al. 2022. J Cell Biochem. 123:1966. PubMed
  5. Albayrak E, et al. 2022. J Cell Biochem. 123:2009. PubMed
  6. Wang H, et al. 2022. Oxid Med Cell Longev. 2022:3082969. PubMed
  7. Ferreira-Baptista C, et al. 2022. Bioengineering (Basel). 9: . PubMed
  8. Fu H, et al. 2023. Regen Ther. 22:7. PubMed
  9. Lin L, et al. 2023. Mol Ther Nucleic Acids. 31:88. PubMed
  10. Chen X, et al. 2023. Exp Ther Med. 25:99. PubMed
  11. Lee CW, et al. 2022. J Adv Res. 39:73. PubMed
  12. Bowley TY, et al. 2022. Cancer Res Commun. 2:1436. PubMed
  13. Hua J, et al. 2023. Ann Transl Med. 11:62. PubMed
  14. Uzieliene I, et al. 2023. Int J Mol Sci. 24:. PubMed
  15. Pal D, et al. 2023. Nat Commun. 14:1129. PubMed
  16. Che L, et al. 2023. Foods. 12:. PubMed
  17. Wan L, et al. 2023. PeerJ. 11:e15164. PubMed
  18. Ishiuchi N, et al. 2023. Stem Cell Res Ther. 14:121. PubMed
  19. Lu Y, et al. 2023. Sci Rep. 13:8479. PubMed
  20. Hu H, et al. 2023. Front Mol Neurosci. 16:1179175. PubMed
  21. Miksiunas R, et al. 2021. Int J Mol Sci. 22:. PubMed
  22. Wu J, et al. 2022. Nat Commun. 13:676. PubMed
  23. Peng K, et al. 2020. Sci Rep. 10:18433. PubMed
  24. Yan H, et al. 2020. Adv Sci (Weinh). 7:1903516. PubMed
  25. Xin Y, et al. 2021. Stem Cell Res Ther. 49:12. PubMed
  26. Li L, et al. 2015. Int J Pharmaceutics. 488: 1-11. PubMed
  27. Liu X, et al. 2020. Exp Ther Med. 1.258333333. PubMed
  28. Chen X, et al. 2022. Front Bioeng Biotechnol. 10:915181. PubMed
  29. Yu XX, et al. 2021. Cell Res. 31:886. PubMed
  30. Radhakrishnan S, et al. 2019. Mol Med Rep. 20:813. PubMed
  31. Shi L, et al. 2021. Stem Cell Res Ther. 12:147. PubMed
  32. Huang X, et al. 2019. Oxid Med Cell Longev. 2019:1305049. PubMed
  33. Vishnoi M, et al. 2018. Cancer Res. 78:5349. PubMed
  34. Tu S, et al. 2020. Cellular Signalling. 73:109695. PubMed
  35. Guney-Esken G, et al. 2021. Stem Cell Res Ther. 12:287. PubMed
  36. Takao T, et al. 2022. STAR Protoc. 3:101786. PubMed
  37. Qin XY, et al. 2020. Cell Death Dis. 0.504166667. PubMed
  38. Hwang Y, et al. 2021. Int J Mol Sci. 22:. PubMed
  39. Dregalla RC, et al. 2021. Stem Cell Res Ther. 12:547. PubMed
  40. Nguyen MAT, et al. 2020. Immunohorizons. 0.465277778. PubMed
  41. Han X, et al. 2020. Int J Oral Sci. 12:10. PubMed
  42. Liu Z, et al. 2021. Molecules. 26:. PubMed
  43. Sun W, et al. 2019. Exp Ther Med. 17:2199. PubMed
  44. Hanse E, et al. 2017. Oncogene. 10.1038/onc.2017.36. PubMed
  45. Albayrak E, et al. 2021. J Cell Physiol. 236:8122. PubMed
  46. Liu Y, et al. 2022. iScience. 25:104405. PubMed
  47. Yu C, et al. 2020. Sci Rep. 10:14521. PubMed
  48. Yan K, et al. 2022. iScience. 25:104822. PubMed
  49. Kinchen J et al. 2018. Cell. 175(2):372-386 . PubMed
  50. Gao P, et al. 2017. Cytotechnology. 69:751. PubMed
  51. Nguyen JT, et al. 2019. iScience. 17:190. PubMed
  52. DAgostino S, et al. 2021. Frontiers in Oncology. 10:600980. PubMed
  53. Duan X, et al. 2022. Cell Biosci. 12:60. PubMed
  54. Fawkner-Corbett D, et al. 2021. STAR Protoc. 2:100890. PubMed
  55. Yang C et al. 2019. Int J Mol Med. 43(3):1395-1405 . PubMed
  56. Zhang S, et al. 2021. Stem Cells Int. 6616240:2021. PubMed
  57. Uslu M, et al. 2020. J Cell Physiol. 235:9644. PubMed
  58. Tidu F, et al. 2021. iScience. 24(6):102683. PubMed
  59. Ayhan S, et al. 2021. Journal of Cell Science. 134(6):. PubMed
  60. Zhang Y, et al. 2019. Aging (Albany NY). 11:12641. PubMed
  61. Cai S, et al. 2022. Cell Biosci. 12:115. PubMed
  62. Zhang Y, et al. 2018. Stem Cells Int. 2018:7159465. PubMed
  63. Noz MP, et al. 2020. Elife. 9:00. PubMed
  64. Sun T, et al. 2019. Haematologica. 105:661. PubMed
  65. Guney-Esken G, et al. 2021. Methods Mol Biol. 2549:23. PubMed
  66. Motedayyen H, et al. 2017. BMC Res Notes. . 10.1186/s13104-017-2880-6. PubMed
  67. Narakornsak S, et al. 2017. Acta Histochemica. 10.1016/j.acthis.2017.04.006. PubMed
  68. Keshtkar S, et al. 2021. Stem Cells Int. 8857457:2020. PubMed
  69. Okamura G, et al. 2020. Int J Mol Sci. 22:00. PubMed
  70. Zhang H, et al. 2017. Oncogene. 10.1038/onc.2016.512. PubMed
  71. Aomatsu E, et al. 2014. Sci Rep. 4:3652. PubMed
  72. Miksiunas R, et al. 2022. Cells. 11:. PubMed
  73. He Z, et al. 2020. J Exp Clin Cancer Res. 39:140. PubMed
  74. Xu L, et al. 2022. Int J Mol Sci. 23:. PubMed
  75. Fawkner-Corbett D, et al. 2021. Cell. 184(3):810-826.e23. PubMed
  76. Meng Z, et al. 2013. Mol Cancer Ther. 12:2067. PubMed
  77. He H, et al. 2019. J Cell Mol Med. 23:4139. PubMed
  78. Zhu YP et al. 2018. Cell reports. 24(9):2329-2341 . PubMed
  79. Pauken CM, et al. 2021. Cancers (Basel). 13:. PubMed
  80. Patel C, et al. 2022. Curr Protoc. 2:e400. PubMed
  81. Vishnoi M, et al. 2019. Mol Oncol. 13(9): 1913. PubMed
  82. Putra I, et al. 2021. Transl Vis Sci Technol. 10:3. PubMed
  83. Matheni C, et al. 2021. Cell J. 23:145. PubMed
  84. Miksiunas R, et al. 2020. Int J Mol Sci. 21:00. PubMed
  85. Luzuriaga J, et al. 2020. Biomedicines. 8:00. PubMed
  86. Hong Y, et al. 2020. Aging Cell. 19:e13128. PubMed
  87. Dinh HQ, et al. 2020. Immunity. 53(2):319-334.e6. PubMed
  88. Thiel A, et al. 2015. Sci Rep. 5: 17685. PubMed
  89. Chijimatsu R, et al. 2022. Regen Ther. 21:52. PubMed
  90. Shang W, et al. 2022. Dis Markers. 2022:7286645. PubMed
  91. Sprouse ML, et al. 2019. Int J Mol Sci. 20:8. PubMed
  92. Khanh VC, et al. 2021. Stem Cells Dev. 30:758. PubMed
  93. Camerlingo R, et al. 2011. Lung Cancer. 72:23. PubMed
  94. Liu T, et al. 2020. Biochem Biophys Res Commun. 532:385. PubMed
  95. Zhang T, et al. 2022. IUBMB Life. 74:1081. PubMed
  96. Yüce M, et al. 2022. J Cell Biochem. 123:1966. PubMed
  97. Albayrak E, et al. 2022. J Cell Biochem. 123:2009. PubMed
  98. Wang H, et al. 2022. Oxid Med Cell Longev. 2022:3082969. PubMed
  99. Ferreira-Baptista C, et al. 2022. Bioengineering (Basel). 9: . PubMed
  100. Fu H, et al. 2023. Regen Ther. 22:7. PubMed
  101. Lin L, et al. 2023. Mol Ther Nucleic Acids. 31:88. PubMed
  102. Chen X, et al. 2023. Exp Ther Med. 25:99. PubMed
  103. Lee CW, et al. 2022. J Adv Res. 39:73. PubMed
  104. Bowley TY, et al. 2022. Cancer Res Commun. 2:1436. PubMed
  105. Hua J, et al. 2023. Ann Transl Med. 11:62. PubMed
  106. Uzieliene I, et al. 2023. Int J Mol Sci. 24:. PubMed
  107. Pal D, et al. 2023. Nat Commun. 14:1129. PubMed
  108. Che L, et al. 2023. Foods. 12:. PubMed
  109. Wan L, et al. 2023. PeerJ. 11:e15164. PubMed
  110. Ishiuchi N, et al. 2023. Stem Cell Res Ther. 14:121. PubMed
  111. Lu Y, et al. 2023. Sci Rep. 13:8479. PubMed
  112. Hu H, et al. 2023. Front Mol Neurosci. 16:1179175. PubMed
  113. Miksiunas R, et al. 2021. Int J Mol Sci. 22:. PubMed
  114. Wu J, et al. 2022. Nat Commun. 13:676. PubMed
  115. Peng K, et al. 2020. Sci Rep. 10:18433. PubMed
  116. Yan H, et al. 2020. Adv Sci (Weinh). 7:1903516. PubMed
  117. Xin Y, et al. 2021. Stem Cell Res Ther. 49:12. PubMed
  118. Li L, et al. 2015. Int J Pharmaceutics. 488: 1-11. PubMed
  119. Liu X, et al. 2020. Exp Ther Med. 1.258333333. PubMed
  120. Chen X, et al. 2022. Front Bioeng Biotechnol. 10:915181. PubMed
  121. Yu XX, et al. 2021. Cell Res. 31:886. PubMed
  122. Radhakrishnan S, et al. 2019. Mol Med Rep. 20:813. PubMed
  123. Shi L, et al. 2021. Stem Cell Res Ther. 12:147. PubMed
  124. Huang X, et al. 2019. Oxid Med Cell Longev. 2019:1305049. PubMed
  125. Vishnoi M, et al. 2018. Cancer Res. 78:5349. PubMed
  126. Tu S, et al. 2020. Cellular Signalling. 73:109695. PubMed
  127. Guney-Esken G, et al. 2021. Stem Cell Res Ther. 12:287. PubMed
  128. Takao T, et al. 2022. STAR Protoc. 3:101786. PubMed
  129. Qin XY, et al. 2020. Cell Death Dis. 0.504166667. PubMed
  130. Hwang Y, et al. 2021. Int J Mol Sci. 22:. PubMed
  131. Dregalla RC, et al. 2021. Stem Cell Res Ther. 12:547. PubMed
  132. Nguyen MAT, et al. 2020. Immunohorizons. 0.465277778. PubMed
  133. Han X, et al. 2020. Int J Oral Sci. 12:10. PubMed
  134. Liu Z, et al. 2021. Molecules. 26:. PubMed
  135. Sun W, et al. 2019. Exp Ther Med. 17:2199. PubMed
  136. Hanse E, et al. 2017. Oncogene. 10.1038/onc.2017.36. PubMed
  137. Albayrak E, et al. 2021. J Cell Physiol. 236:8122. PubMed
  138. Liu Y, et al. 2022. iScience. 25:104405. PubMed
  139. Yu C, et al. 2020. Sci Rep. 10:14521. PubMed
  140. Yan K, et al. 2022. iScience. 25:104822. PubMed
  141. Kinchen J et al. 2018. Cell. 175(2):372-386 . PubMed
  142. Gao P, et al. 2017. Cytotechnology. 69:751. PubMed
  143. Nguyen JT, et al. 2019. iScience. 17:190. PubMed
  144. DAgostino S, et al. 2021. Frontiers in Oncology. 10:600980. PubMed
  145. Duan X, et al. 2022. Cell Biosci. 12:60. PubMed
  146. Fawkner-Corbett D, et al. 2021. STAR Protoc. 2:100890. PubMed
  147. Yang C et al. 2019. Int J Mol Med. 43(3):1395-1405 . PubMed
  148. Zhang S, et al. 2021. Stem Cells Int. 6616240:2021. PubMed
  149. Uslu M, et al. 2020. J Cell Physiol. 235:9644. PubMed
  150. Tidu F, et al. 2021. iScience. 24(6):102683. PubMed
  151. Ayhan S, et al. 2021. Journal of Cell Science. 134(6):. PubMed
  152. Zhang Y, et al. 2019. Aging (Albany NY). 11:12641. PubMed
  153. Cai S, et al. 2022. Cell Biosci. 12:115. PubMed
  154. Zhang Y, et al. 2018. Stem Cells Int. 2018:7159465. PubMed
  155. Noz MP, et al. 2020. Elife. 9:00. PubMed
  156. Sun T, et al. 2019. Haematologica. 105:661. PubMed
  157. Guney-Esken G, et al. 2021. Methods Mol Biol. 2549:23. PubMed
  158. Motedayyen H, et al. 2017. BMC Res Notes. . 10.1186/s13104-017-2880-6. PubMed
  159. Narakornsak S, et al. 2017. Acta Histochemica. 10.1016/j.acthis.2017.04.006. PubMed
  160. Keshtkar S, et al. 2021. Stem Cells Int. 8857457:2020. PubMed
  161. Okamura G, et al. 2020. Int J Mol Sci. 22:00. PubMed
  162. Zhang H, et al. 2017. Oncogene. 10.1038/onc.2016.512. PubMed
  163. Aomatsu E, et al. 2014. Sci Rep. 4:3652. PubMed
  164. Miksiunas R, et al. 2022. Cells. 11:. PubMed
  165. He Z, et al. 2020. J Exp Clin Cancer Res. 39:140. PubMed
  166. Xu L, et al. 2022. Int J Mol Sci. 23:. PubMed
  167. Fawkner-Corbett D, et al. 2021. Cell. 184(3):810-826.e23. PubMed
  168. Meng Z, et al. 2013. Mol Cancer Ther. 12:2067. PubMed
  169. He H, et al. 2019. J Cell Mol Med. 23:4139. PubMed
  170. Zhu YP et al. 2018. Cell reports. 24(9):2329-2341 . PubMed
  171. Pauken CM, et al. 2021. Cancers (Basel). 13:. PubMed
  172. Patel C, et al. 2022. Curr Protoc. 2:e400. PubMed
  173. Vishnoi M, et al. 2019. Mol Oncol. 13(9): 1913. PubMed
  174. Putra I, et al. 2021. Transl Vis Sci Technol. 10:3. PubMed
  175. Matheni C, et al. 2021. Cell J. 23:145. PubMed
  176. Miksiunas R, et al. 2020. Int J Mol Sci. 21:00. PubMed
  177. Luzuriaga J, et al. 2020. Biomedicines. 8:00. PubMed
  178. Hong Y, et al. 2020. Aging Cell. 19:e13128. PubMed
  179. Dinh HQ, et al. 2020. Immunity. 53(2):319-334.e6. PubMed
  180. Thiel A, et al. 2015. Sci Rep. 5: 17685. PubMed
  181. Chijimatsu R, et al. 2022. Regen Ther. 21:52. PubMed
  182. Shang W, et al. 2022. Dis Markers. 2022:7286645. PubMed
  183. Sprouse ML, et al. 2019. Int J Mol Sci. 20:8. PubMed
  184. Khanh VC, et al. 2021. Stem Cells Dev. 30:758. PubMed
RRID
AB_893438 (BioLegend Cat. No. 328107)
AB_893429 (BioLegend Cat. No. 328108)

Antigen Details

Structure
25-35 kD glycoprotein, Ig superfamily
Distribution

Subset of CD34+ hematopoietic stem cells, subset of fetal thymocytes, subset of fetal liver cells, fibroblast, activated endothelial cells, neurons and some leukemia cell lines

Function
Regulate hematopoiesis and neural cell growth, cell adhesion
Ligand/Receptor
β3 integrin, β2 integrin
Cell Type
Endothelial cells, Fibroblasts, Hematopoietic stem and progenitors, Leukemia, Mesenchymal Stem Cells, Neurons, Thymocytes
Biology Area
Immunology, Stem Cells
Molecular Family
CD Molecules
Antigen References

1. McKenzie JL, et al. 1981. J. Immunol. 126:843.
2. Avalos AM, et al. 2002. Biol. Res. 35:231.
3. Wetzel A, et al. 2004. J. Immunol. 172:3850.

Gene ID
7070 View all products for this Gene ID
UniProt
View information about CD90 on UniProt.org

Other Formats

View All CD90 Reagents Request Custom Conjugation
Description Clone Applications
PE/Cyanine7 anti-human CD90 (Thy1) 5E10 FC
Purified anti-human CD90 (Thy1) 5E10 FC,CyTOF®,IHC-F,ICC,IP
Biotin anti-human CD90 (Thy1) 5E10 FC
FITC anti-human CD90 (Thy1) 5E10 FC
PE anti-human CD90 (Thy1) 5E10 FC
PE/Cyanine5 anti-human CD90 (Thy1) 5E10 FC
APC anti-human CD90 (Thy1) 5E10 FC
Alexa Fluor® 647 anti-human CD90 (Thy1) 5E10 FC
PerCP/Cyanine5.5 anti-human CD90 (Thy1) 5E10 FC
Alexa Fluor® 700 anti-human CD90 (Thy1) 5E10 FC
Brilliant Violet 421™ anti-human CD90 (Thy1) 5E10 FC
Brilliant Violet 510™ anti-human CD90 (Thy1) 5E10 FC
Brilliant Violet 605™ anti-human CD90 (Thy1) 5E10 FC
Purified anti-human CD90 (Thy1) (Maxpar® Ready) 5E10 FC,CyTOF®
APC/Cyanine7 anti-human CD90 (Thy1) 5E10 FC
PE/Dazzle™ 594 anti-human CD90 (Thy1) 5E10 FC
APC/Fire™ 750 anti-human CD90 (Thy1) 5E10 FC
Brilliant Violet 711™ anti-human CD90 (Thy1) 5E10 FC
TotalSeq™-A0060 anti-human CD90 (Thy1) 5E10 PG
Brilliant Violet 785™ anti-human CD90 (Thy1) 5E10 FC
Brilliant Violet 650™ anti-human CD90 (Thy1) 5E10 FC
TotalSeq™-C0060 anti-human CD90 (Thy1) 5E10 PG
TotalSeq™-B0060 anti-human CD90 (Thy1) 5E10 PG
TotalSeq™-D0060 anti-human CD90 (Thy1) 5E10 PG
Spark Red™ 718 anti-human CD90 (Thy1) (Flexi-Fluor™) 5E10 FC
Spark Blue™ 574 anti-human CD90 (Thy1) (Flexi-Fluor™) 5E10 FC
Spark Blue™ 550 anti-human CD90 (Thy1) (Flexi-Fluor™) 5E10 FC
Spark PLUS UV395™ anti-human CD90 (Thy1) 5E10 FC
Go To Top Version: 3    Revision Date: 08/04/2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account